<- Go Home
Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Market Cap
$425.4M
Volume
2.5M
Cash and Equivalents
$92.7M
EBITDA
-$178.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$6.42
52 Week Low
$2.71
Dividend
N/A
Price / Book Value
3.34
Price / Earnings
-2.12
Price / Tangible Book Value
3.34
Enterprise Value
$274.1M
Enterprise Value / EBITDA
-1.54
Operating Income
-$179.0M
Return on Equity
139.63%
Return on Assets
-70.96
Cash and Short Term Investments
$156.3M
Debt
$5.0M
Equity
$127.4M
Revenue
N/A
Unlevered FCF
-$94.2M
Sector
Biotechnology
Category
N/A